Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $15.83

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $15.83.

Several equities analysts recently weighed in on the company. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus cut their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Leerink Partners began coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Finally, Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $11.33 on Friday. The company’s fifty day moving average is $11.70 and its two-hundred day moving average is $13.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market capitalization of $5.60 billion, a P/E ratio of 28.33, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a one year low of $10.20 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the firm posted $0.08 EPS. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. Analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth about $29,000. AM Squared Ltd acquired a new stake in Elanco Animal Health during the third quarter worth approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health during the third quarter worth approximately $35,000. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC lifted its stake in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.